Jardiance

Most-clicked pharma news for week ending April 1 2023: Signify Health acquisition, Ferring Research Institute shutdown, Jardiance sales increase, and more
Most-clicked pharma news for week ending April 1 2023: Signify Health acquisition, Ferring Research Institute shutdown, Jardiance sales increase, and more
CP Wire
CVS Health
Signify Health
M&A
Ferring Pharmaceuticals
Pfizer
Bristol Myers Squibb
Eli Lilly
Novo Nordisk
Boehringer Ingelheim
Jardiance
Ozempic
drug pricing
Eliquis
CMS
Flag link:
Most-clicked pharma news for week ending April 1 2023: Signify Health acquisition, Ferring Research Institute shutdown, Jardiance sales increase, and more
CVS Health
Signify Health
M&A
Ferring Pharmaceuticals
Pfizer
Bristol Myers Squibb
Eli Lilly
Novo Nordisk
Boehringer Ingelheim
Jardiance
Ozempic
drug pricing
Eliquis
CMS
Flag link:
Boehringer Ingelheim and Eli Lilly's Jardiance gets big lift from heart failure indications
Boehringer Ingelheim and Eli Lilly's Jardiance gets big lift from heart failure indications
Fierce Pharma
Boehringer Ingelheim
Eli Lilly
Jardiance
heart failure
Flag link:
Top 10 Pharma TV Ad Spenders in 2022 — Anti-Inflammatories and Diabetes Drugs Dominate
Top 10 Pharma TV Ad Spenders in 2022 — Anti-Inflammatories and Diabetes Drugs Dominate
Xtalks
television ads
pharma marketing
DTC ads
AbbVie
Rinvoq
Dupixent
Sanofi
Regeneron
Skyrizi
Novo Nordisk
Ozempic
Jardiance
Eli Lilly
Boehringer Ingelheim
Rybelsus
Trulicity
Rexulti
Otsuka
Lundbeck
Tremfya
JNJ
Verzenio
Flag link:
Lilly and Boehringer's Jardiance Racks Up Another Type 2 Diabetes Win
Lilly and Boehringer's Jardiance Racks Up Another Type 2 Diabetes Win
BioSpace
Eli Lilly
Boehringer Ingelheim
type 2 diabetes
Jardiance
pediatri
Flag link:
Eli Lilly, Boehringer Ingelheim bolster case for Jardiance to treat chronic kidney disease
Eli Lilly, Boehringer Ingelheim bolster case for Jardiance to treat chronic kidney disease
Fierce Pharma
Eli Lilly
Boehringer Ingelheim
chronic kideny disease
Jardiance
Farxiga
AstraZeneca
Flag link:
Eli Lilly, Boehringer Ingelheim's Jardiance turns up heat on AstraZeneca's Farxiga with broad EU heart failure approval
Eli Lilly, Boehringer Ingelheim's Jardiance turns up heat on AstraZeneca's Farxiga with broad EU heart failure approval
Fierce Pharma
Eli Lilly
Boehringer Ingelheim
Jardiance
heart failure
Europe
AstraZeneca
Farxiga
Flag link:
Eli Lilly, Boehringer Ingelheim's Jardiance clinches heart failure edge with FDA nod for wider label
Eli Lilly, Boehringer Ingelheim's Jardiance clinches heart failure edge with FDA nod for wider label
Fierce Pharma
Eli Lilly
Boehringer Ingelheim
Jardiance
heart failure
FDA
Flag link:
Boehringer-Lilly’s Jardiance obtains FDA priority review to treat heart failure
Boehringer-Lilly’s Jardiance obtains FDA priority review to treat heart failure
Pharmaceutical Business Review
Eli Lilly
Boehringer Ingelheim
Jardiance
priority review
FDA
heart failure
Flag link:
Eli Lilly, Boehringer roll out video game for doctors to highlight cardio-renal-metabolic disease connections
Eli Lilly, Boehringer roll out video game for doctors to highlight cardio-renal-metabolic disease connections
Fierce Pharma
Eli Lilly
Boehringer Ingelheim
Jardiance
diabetes
gamification
Flag link:
Here's What This Label Expansion Could Mean for Eli Lilly Investors
Here's What This Label Expansion Could Mean for Eli Lilly Investors
Motley Fool
Eli Lilly
Jardiance
heart failure
label expansions
FDA
Flag link:
FDA Approvals Roundup: Korsuva, Jardiance, Xarelto
FDA Approvals Roundup: Korsuva, Jardiance, Xarelto
RAPS.org
Cara Therapeutics
Korsuva
Boehringer Ingelheim
Jardiance
Bristol Myers Squibb
Opdivo
Flag link:
Jardiance gets parity with Farxiga in US as FDA clears use in heart failure
Jardiance gets parity with Farxiga in US as FDA clears use in heart failure
Pharmaforum
Eli Lilly
Boehringer Ingelheim
FDA
diabetes
Jardiance
heart failure with reduced ejection fraction
Flag link:
Eli Lilly, Boehringer Ingelheim tout pivotal heart failure win for Jardiance, potentially setting up a Novartis showdown
Eli Lilly, Boehringer Ingelheim tout pivotal heart failure win for Jardiance, potentially setting up a Novartis showdown
Endpoints
Eli Lilly
Boehringer Ingelheim
heart failure
clinical trials
Jardiance
Flag link:
Farxiga faces first heart failure rival as EU OKs Boehringer/Lilly’s Jardiance
Farxiga faces first heart failure rival as EU OKs Boehringer/Lilly’s Jardiance
Pharmaforum
AstraZeneca
Farxiga
heart failure
Boehringer Ingelheim
Eli Lilly
Jardiance
Flag link:
Boehringer, Lilly’s Jardiance ties to match AZ’s Farxiga with heart failure label
Boehringer, Lilly’s Jardiance ties to match AZ’s Farxiga with heart failure label
Pharmaforum
Boehringer Ingelheim
Eli Lilly
Jardiance
FDA
heart failure
fast track
Flag link:
ESC 2020 – Jardiance joins Farxiga in showing heart failure benefit
ESC 2020 – Jardiance joins Farxiga in showing heart failure benefit
EP Vantage
ESC
Eli Lilly
Boehringer Ingelheim
Farxiga
Jardiance
heart failure
AstraZeneca
Flag link:
Boehringer and Lilly’s Jardiance Hits Mark in Decreasing Risk of Death in Heart Failure
Boehringer and Lilly’s Jardiance Hits Mark in Decreasing Risk of Death in Heart Failure
BioSpace
Boehringer Ingelheim
Eli Lilly
Jardiance
heart failure
diabetes
clinical trials
Flag link:
FDA blocks Lilly, Boehringer's Jardiance from coveted Type 1 diabetes nod
FDA blocks Lilly, Boehringer's Jardiance from coveted Type 1 diabetes nod
Fierce Pharma
Eli Lilly
Boehringer Ingelheim
Jardiance
type 1 diabetes
diabetes
empagliflozin
Flag link:
Lilly and Boehringer's Jardiance, chasing AZ, nabs speedy FDA review in kidney disease
Lilly and Boehringer's Jardiance, chasing AZ, nabs speedy FDA review in kidney disease
Fierce Pharma
Eli Lilly
Boehringer Ingelheim
AstraZeneca
FDA
Jardiance
kidney disease
Flag link:

Pages